MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2022008916

Медицинская библиотека · Blood advances · 2023

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.

Sawalha Yazeed, Goyal Subir, Switchenko Jeffrey M, Romancik Jason T, Kamdar Manali, Greenwell I Brian, Hess Brian T, Isaac Krista M, Portell Craig A, Mejia Garcia Alex, Goldsmith Scott, Grover Natalie S, Riedell Peter A, Karmali Reem, Burkart Madelyn, Buege Michael, Akhtar Othman, Torka Pallawi, Kumar Anita, Hill Brian T, Kahl Brad S, Cohen Jonathon B

Многоцентровое исследованиеСтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n = 50, 62%) or in combination with a Bruton tyrosine kinase inhibitor (BTKi) (n = 16, 20%), an anti-CD20 monoclonal antibody (n = 11, 14%), or other active agents at 12 US academic medical centers. Patients had high-risk disease features including Ki67 >30% (61%), blastoid/pleomorphic histology (29%), complex karyotype (34%), and TP53 alterations (49%), and received a median of 3 prior treatments including BTKis in 91%. Venetoclax alone or in combination resulted in an overall response rate (ORR) of 40% and median progression-free (PFS) and overall survival (OS) of 3.7 and 12.5 months, respectively. The receipt of ≤3 prior treatments was associated with higher odds of response to venetoclax in a univariable analysis. In a multivariable analysis, having a high-risk Mantle Cell Lymphoma International Prognostic Index score before receiving venetoclax and disease relapse or progression within 24 months of diagnosis were associated with inferior OS whereas the use of venetoclax in combination was associated with superior OS. Although most patients (61%) had low risk for tumor lysis syndrome (TLS), 12.3% of patients developed TLS despite the implementation of several mitigation strategies. In conclusion, venetoclax resulted in good ORR but short PFS in patients with MCL who are at high risk, and may have a better role in earlier lines of treatment and/or in conation with other active agents. TLS remains an important risk in patients with MCL who initiate treatment with venetoclax.

Для цитирования: Sawalha Yazeed, Goyal Subir, Switchenko Jeffrey M, Romancik Jason T, Kamdar Manali, Greenwell I Brian, Hess Brian T, Isaac Krista M, Portell Craig A, Mejia Garcia Alex, Goldsmith Scott, Grover Natalie S, Riedell Peter A, Karmali Reem, Burkart Madelyn, Buege Michael, Akhtar Othman, Torka Pallawi, Kumar Anita, Hill Brian T, Kahl Brad S, Cohen Jonathon B. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.. Blood advances. 2023. DOI: 10.1182/bloodadvances.2022008916.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.